Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026827 (
hypotonia
)
5,860
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Biallelic mutations of
UBE3B
have recently been shown to cause Kaufman oculocerebrofacial syndrome (also reported as blepharophimosis-ptosis-intellectual disability syndrome), an autosomal recessive condition characterized by
hypotonia
, developmental delay, intellectual disability, congenital anomalies, characteristic facial dysmorphic features, and low cholesterol levels. To date, six patients with either missense mutations affecting the
UBE3B
HECT domain or truncating mutations have been described. Here, we report on the identification of homozygous or compound heterozygous
UBE3B
mutations in six additional patients from five unrelated families using either targeted
UBE3B
sequencing in individuals with suggestive facial dysmorphic features, or exome sequencing. Our results expand the clinical and mutational spectrum of the
UBE3B
-related disorder in several ways. First, we have identified
UBE3B
mutations in individuals who previously received distinct clinical diagnoses: two sibs with Toriello-Carey syndrome as well as the patient reported to have a "new" syndrome by Buntinx and Majewski in 1990. Second, we describe the adult phenotype and clinical variability of the syndrome. Third, we report on the first instance of homozygous missense alterations outside the HECT domain of
UBE3B
, observed in a patient with mildly dysmorphic facial features. We conclude that
UBE3B
mutations cause a clinically recognizable and possibly underdiagnosed syndrome characterized by distinct craniofacial features,
hypotonia
, failure to thrive, eye abnormalities, other congenital malformations, low cholesterol levels, and severe intellectual disability. We review the
UBE3B
-associated phenotypes, including forms that can mimick Toriello-Carey syndrome, and suggest the single designation "Kaufman oculocerebrofacial syndrome".
...
PMID:Expanding the clinical and mutational spectrum of Kaufman oculocerebrofacial syndrome with biallelic UBE3B mutations. 2461 90
Recent genome-wide studies found that patients with
hypotonia
, developmental delay, intellectual disability, congenital anomalies, characteristic facial dysmorphic features, and low cholesterol levels suffer from
K
aufman
o
culocerebrofacial
s
yndrome (KOS, also reported as blepharophimosis-ptosis-intellectual disability syndrome). The primary cause of KOS is autosomal recessive mutations in the gene
UBE3B
However, to date, there are no studies that have determined the cellular or enzymatic function of
UBE3B
. Here, we report that
UBE3B
is a mitochondrion-associated protein with
h
omologous to the
E
6-AP
C
t
erminus (HECT) E3 ubiquitin ligase activity. Mutating the catalytic cysteine (C1036A) or deleting the entire HECT domain (amino acids 758-1068) results in loss of
UBE3B
's ubiquitylation activity. Knockdown of
UBE3B
in human cells induces changes in mitochondrial morphology and physiology, a decrease in mitochondrial volume, and a severe suppression of cellular proliferation. We also discovered that
UBE3B
interacts with calmodulin via its N-terminal isoleucine-glutamine (IQ) motif. Deletion of the IQ motif (amino acids 29-58) results in loss of calmodulin binding and a significant increase in the
in vitro
ubiquitylation activity of
UBE3B
. In addition, we found that changes in calcium levels
in vitro
disrupt the calmodulin-
UBE3B
interaction. These studies demonstrate that
UBE3B
is an E3 ubiquitin ligase and reveal that the enzyme is regulated by calmodulin. Furthermore, the modulation of
UBE3B
via calmodulin and calcium implicates a role for calcium signaling in mitochondrial protein ubiquitylation, protein turnover, and disease.
...
PMID:UBE3B Is a Calmodulin-regulated, Mitochondrion-associated E3 Ubiquitin Ligase. 2800 68